Identification of minority resistance mutations in the HIV-1 integrase coding region using next generation sequencing

Journal of Clinical Virology

Volumn 73, Issue , 2015, Pages 95-100

  Fonager, Jannik ^a   Larsson, Jonas T ^a   Hussing, Christian ^a   Neess Engsig, Frederik ^b   Nielsen, Claus ^a   Fischer, Thea Kølsen ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

Deep sequencing; Hiv 1; Illumina MiSeq; Integrase; Minority variants; Resistance

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR; FUSED HETEROCYCLIC RINGS; QUINOLONE DERIVATIVE;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC VARIABILITY; GENOMICS; HUMAN IMMUNODEFICIENCY VIRUS 1; LIMIT OF DETECTION; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SANGER POPULATION SEQUENCING; VIRUS GENOME; VIRUS MUTATION; ADOLESCENT; COMPARATIVE STUDY; ENZYMOLOGY; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; MUTATION; PRESCHOOL CHILD; PROCEDURES; SEQUENCE ANALYSIS;

ADOLESCENT; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INTEGRASE; HIV-1; HUMANS; MUTATION; QUINOLONES; RALTEGRAVIR POTASSIUM; SEQUENCE ANALYSIS, RNA;

EID: 84949447160     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.11.009     Document Type: Article

References (42)

1. Cohen M.S., Chen Y.Q., McCauley M., Gamble T., Hosseinipour M.C., Kumarasamy N., et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 2011, 365(August 11 (6)):493-505.
2. Montaner J.S., Lima V.D., Harrigan P.R., Lourenco L., Yip B., Nosyk B., et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the HIV treatment as prevention experience in a Canadian setting. PLoS One 2014, 9(2):e87872.
3. Pham Q.D., Wilson D.P., Law M.G., Kelleher A.D., Zhang L. Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS 2014, 28(November 28 (18)):2751-2762.
4. Trotter A.B., Hong S.Y., Srikantiah P., Abeyewickreme I., Bertagnolio S., Jordan M.R. Systematic review of HIV drug resistance in Southeast Asia. AIDS Rev. 2013, 15(July (3)):162-170.
5. Hosseinipour M.C., Gupta R.K., Van Z.G., Eron J.J., Nachega J.B. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J. Infect. Dis. 2013, 207(June 15 (Suppl 2)):S49-S56.
6. Franzetti M., Violin M., Antinori A., De L.A., Ceccherini-Silberstein F., Gianotti N., et al. Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy. BMC Infect. Dis. 2014, 14:398.
7. Leitner T., Halapi E., Scarlatti G., Rossi P., Albert J., Fenyo E.M., et al. Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques 1993, 15(July (1)):120-127.
8. Church J.D., Jones D., Flys T., Hoover D., Marlowe N., Chen S., et al. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J. Mol. Diagn. 2006, 8(September (4)):430-432.
9. Larder B.A., Kohli A., Kellam P., Kemp S.D., Kronick M., Henfrey R.D. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993, 365(October 14 (6447)):671-673.
10. Halvas E.K., Aldrovandi G.M., Balfe P., Beck I.A., Boltz V.F., Coffin J.M., et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol. 2006, 44(July (7)):2612-2614.
11. Goodman D.D., Zhou Y., Margot N.A., McColl D.J., Zhong L., Borroto-Esoda K., et al. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 2011, 25(January 28 (3)):325-333.
12. Li J.Z., Kuritzkes D.R. Clinical implications of HIV-1 minority variants. Clin. Infect. Dis. 2013, 56(June (11)):1667-1674.
13. Gibson R.M., Meyer A.M., Winner D., Archer J., Feyertag F., Ruiz-Mateos E., et al. Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. Antimicrob. Agents Chemother. 2014, 58(4):2167-2185.
14. Li J.Z., Chapman B., Charlebois P., Hofmann O., Weiner B., Porter A.J., et al. Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. PLoS One 2014, 9(3):e90485.
15. Lee G.Q., Swenson L.C., Poon A.F., Martin J.N., Hatano H., Deeks S.G., et al. Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 deep sequencing. PLoS One 2012, 7(9):e46181.
16. Swenson L.C., Daumer M., Paredes R. Next-generation sequencing to assess HIV tropism. Curr. Opin. HIV AIDS 2012, 7(September (5)):478-485.
17. Avidor B., Girshengorn S., Matus N., Talio H., Achsanov S., Zeldis I., et al. Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory. J. Clin. Microbiol. 2013, 51(March (3)):880-886.
18. Nicot F., Saune K., Raymond S., Jeanne N., Carcenac R., Lefebvre C., et al. Minority resistant HIV-1 variants and the response to first-line NNRTI therapy. J. Clin. Virol. 2015, 62(January):20-24.
19. Todesco E., Rodriguez C., Morand-Joubert L., Mercier-Darty M., Desire N., Wirden M., et al. Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing. J. Antimicrob. Chemother. 2015, 21(January).
20. Vandenhende M.A., Bellecave P., Recordon-Pinson P., Reigadas S., Bidet Y., Bruyand M., et al. Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure. PLoS One 2014, 9(1):e86771.
21. Fernandez-Caballero J.A., Chueca N., Alvarez M., Gonzalez D., Garcia F. Use of deep sequencing data for routine analysis of HIV resistance in newly diagnosed patients. J. Int. AIDS Soc. 2014, 17(4 (Suppl 3)):19748.
22. Hauser A., Mugenyi K., Kabasinguzi R., Bluethgen K., Kuecherer C., Harms G., et al. Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR. Antimicrob. Agents Chemother. 2009, 53(July (7)):2965-2973.
23. Hunt G.M., Morris L., Moorthy A., Coovadia A., Abrams E.J., Strehlau R., et al. Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J. Virol. Methods 2014, 207(October):182-187.
24. EACS, 2015. http://www.eacsociety.org/files/guidelines-7.1-english.pdf.
25. Engsig F.N., Gerstoft J., Kronborg G., Larsen C.S., Pedersen G., Audelin A.M., et al. Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen. Clin. Epidemiol. 2010, 2:145-151.
26. Menendez-Arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res. 2013, 98(April (1)):93-120.
27. Blanco J.L., Varghese V., Rhee S.Y., Gatell J.M., Shafer R.W. HIV-1 integrase inhibitor resistance and its clinical implications. J. Infect. Dis. 2011, 203(May 1 (9)):1204-1214.
28. Blanco Arevalo J.L., Whitlock G.G. Dolutegravir an exciting new kid on the block. Expert Opin. Pharmacother. 2014, 15(March (4)):573-582.
29. Mesplede T., Quashie P.K., Zanichelli V., Wainberg M.A. Integrase strand transfer inhibitors in the management of HIV-positive individuals. Ann. Med. 2014, 46(May (3)):123-129.
30. de Souza C.J., Ferreira J.L., Guimaraes P.M., Vidal J.E., Brigido L.F. High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen. J. Antimicrob. Chemother. 2015, 70(March (3)):926-929.
31. Dudley D.M., Bailey A.L., Mehta S.H., Hughes A.L., Kirk G.D., Westergaard R.P., et al. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq. Retrovirology 2014, 11(December 23 (1)):122.
32. Los Alamos Hiv sequence database, 2015. http://www.hiv.lanl.gov/content/sequence/HIV/REVIEWS/RefSeqs2005/RefSeqs05htm.
33. HIVdb, 2015. http://sierra2stanford.edu/sierra/servlet/JSierra%3Faction=sequenceInput.
34. Mohamed S., Penaranda G., Gonzalez D., Camus C., Khiri H., Boulme R., et al. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure. AIDS 2014, 28(June 1 (9)):1315-1324.
35. Le T., Chiarella J., Simen B.B., Hanczaruk B., Egholm M., Landry M.L., et al. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 2009, 4(6):e6079.
36. ART recommendations, 2015. http://https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/6/drug-resistance-testing.
37. Brodin J., Mild M., Hedskog C., Sherwood E., Leitner T., Andersson B., et al. PCR-induced transitions are the major source of error in cleaned ultra-deep pyrosequencing data. PLoS One 2013, 8(7):e70388.
38. Orton R.J., Wright C.F., Morelli M.J., King D.J., Paton D.J., King D.P., et al. Distinguishing low frequency mutations from RT-PCR and sequence errors in viral deep sequencing data. BMC Genomics 2015, 16:229.
39. Charpentier C., Laureillard D., Piketty C., Tisserand P., Batisse D., Karmochkine M., et al. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 2010, 24(March 27 (6)):867-873.
40. Gianella S., Delport W., Pacold M.E., Young J.A., Choi J.Y., Little S.J., et al. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J. Virol. 2011, 85(August (16)):8359-8367.
41. Li J.Z., Paredes R., Ribaudo H.J., Svarovskaia E.S., Metzner K.J., Kozal M.J., et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011, 305(April 6 (13)):1327-1335.
42. Messiaen P., Verhofstede C., Vandenbroucke I., Dinakis S., Van E., Thys V.K., et al. Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. Virology 2012, 426(Apr 25 (1)):7-11.